Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of the Concomitant Administration of Indoximod Plus Immune Checkpoint Inhibitors for Adult Patients With Advanced or Metastatic Melanoma

NCT02073123 is registered in ClinicalTrials.gov with NewLink Genetics Corporation as lead sponsor.

NCT NCT02073123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02073123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of the Concomitant Administration of Indoximod Plus Immune Checkpoint Inhibitors for Adult Patients With Advanced or Metastatic Melanoma
Lead sponsor
NewLink Genetics Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2014
Completion date
July 3, 2019
Enrollment
131 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma, stage iii melanoma, stage iv melanoma